



Practitioner's Docket No. MPI98-148P1USRCE2M

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Phillips, David R., et al.
Application No.: 09/673,302 Group No.: 1632
Filed: March 23, 2001 Examiner: Ton, Thaian N.
For: TRANSGENIC MICE EXPRESSING MUTANT GP IIIA (β 3) PROTEIN

Mail Stop RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

**SUBMISSION OF "SEQUENCE LISTING," COMPUTER READABLE COPY,
AND/OR AMENDMENT PERTAINING THERETO
FOR BIOTECHNOLOGY INVENTION CONTAINING NUCLEOTIDE
AND/OR AMINO ACID SEQUENCE**

1. This replies to the Office communication dated July 12, 2004.

A copy of the Office communication is enclosed.

IDENTIFICATION OF PERSON MAKING STATEMENT

2. I, Tracy M. Sioussat

(*type or print name of person signing below*)

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

deposited with the United States Postal Service in an envelope addressed to Mail Stop RCE, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

37 C.F.R. SECTION 1.8(a)

37 C.F.R. SECTION 1.10*

with sufficient postage as first class mail.

as "Express Mail Post Office to Address"
Mailing Label No. EV512402416US

TRANSMISSION

transmitted by facsimile to the Patent and Trademark Office.

Beverly Sotiropoulos
Signature

Date: July 23, 2004

Beverly Sotiropoulos
(*type or print name of person certifying*)

***WARNING:** Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

ITEMS BEING SUBMITTED

3. Submitted herewith are:

- A. "Sequence Listing(s)" for the nucleotide and/or amino acid sequence(s) in this application (5 pages). Each "Sequence Listing" is assigned a separate identifier as required in 37 C.F.R. Section 1.821(c) and 37 C.F.R. Sections 1.822 and 1.823.
- B. An amendment to the description and/or claims, wherein reference is made to the sequence by use of the assigned identifier, as required in 37 C.F.R. Section 1.821(d).
- C. A copy of each "Sequence Listing" submitted for this application in computer readable form, in accordance with the requirements of 37 C.F.R. Sections 1.821(e) and 1.824.
- D. Please transfer to this application, in accordance with 37 C.F.R. Section 1.821(e), the computer readable copy(ies) from applicant's other application identified as follows:

In re application of:			
Application No.:		Group No.:	
Filed:		Examiner:	
For:			

The Computer readable form(s) of applicant's other application corresponds to the "Sequence Identifier(s)" of the application as follows:

Computer Readable Form	"Sequence Identifier"
(other application)	(this application)

- E. A statement that the content of each "Sequence Listing" submitted and each computer readable copy are the same, as required in 37 C.F.R. Section 1.821(f).
 - Because the statement is not made by a person registered to practice before the Office, the Statement is verified as required in 37 C.F.R. Section 1.821(b).
- F. Because this submission is made in fulfilling the requirement under 37 C.F.R. Section 1.821(g), a statement that the submission includes no new matter.

Practitioner's Docket No. MPI98-148P1USRCE2M

- [] Because the statement is not made by a person registered to practice before the Office, the statement is verified, as required in 37 C.F.R. Section 1.821(g).

**STATEMENT THAT "SEQUENCE LISTING"
AND COMPUTER READABLE COPY ARE THE SAME
AND/OR THAT PAPERS SUBMITTED INCLUDES NO NEW MATTER**

4. I hereby state:

- A. [x] Each computer readable form submitted in this application, including those forms requested to be transferred from applicant's other application, is the same as the "Sequence Listing" to which it is indicated to relate.
- B. [x] All papers accompanying this submission, or for which a request for transfer from applicants' other application, introduce no new matter.

FEE DEFICIENCY

5. [x] If any additional extension and/or fee is required, charge Account No. 501668.

July 23, 2004

MILLENNIUM PHARMACEUTICALS, INC.

By Tracy M. Sioussat
Tracy M. Sioussat, Ph.D.
Registration No. 50,609
40 Landsdowne Street
Cambridge, MA 02139
Telephone – (617) 374-7679
Facsimile – (617) 551-8820